SpaceX and Cerebras Compete in AI Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 01 2026
0mins
Source: NASDAQ.COM
- SpaceX IPO Prospects: SpaceX is expected to become the largest IPO in history, with CEO Elon Musk's promotional skills likely driving its valuation close to $2 trillion, despite its AI business not yet being profitable, indicating significant market anticipation for space data centers.
- Starlink User Growth: SpaceX's Starlink satellite internet service has seen its subscriber base grow from 2.3 million at the end of 2023 to 10.3 million by Q1 2026, with Q1 revenue increasing by 32% to $3.3 billion and operating income rising 15% to $1.2 billion, showcasing its strong recurring revenue capabilities in a competitive market.
- Cerebras Technology Edge: Cerebras' chips perform inference 15 times faster than GPUs by integrating static random-access memory (SRAM) directly, and although its systems are pricey and niche, OpenAI's commitment of over $20 billion for its servers highlights its market potential.
- Market Competition and Challenges: While SpaceX's space data center concept is eye-catching, it faces technical hurdles such as chip lifespan, cooling, and cosmic radiation, whereas Cerebras must prove it can move beyond being a niche player to capture a larger share of the AI inference market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CBRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CBRS
Wall Street analysts forecast CBRS stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 201.010
Low
Averages
High
Current: 201.010
Low
Averages
High
No data
About CBRS
Cerebras Systems Inc. is an artificial intelligence (AI) infrastructure company that designs and manufactures an AI compute platform comprised of proprietary systems and software. The Company's products include inference Cloud, Training Cloud, CS-3 system, AI supercomputer, Wafer Scale Engine and model development. The Company's pioneering Wafer-Scale Engine (WSE), a chip encompassing an entire silicon wafer, was specifically designed to enable higher performance and speeds than GPUs for the computational demands of inference, Generative AI (GenAI), and other AI applications. It offers deployment services to assist customers with data preparation, model architecture design, training management, inference optimization, and, in select cases, ongoing system operations and management. It also offers a subscription service providing access to an ongoing stream of software updates and upgrades for purchasers of its hardware.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cerebras Shares Rebound as Wall Street Initiates Coverage
- Positive Market Reaction: Cerebras shares rose 5% in premarket trading on Monday, reflecting investor confidence in the newly public chipmaker, particularly after Wall Street initiated coverage, indicating recognition of its unique capabilities.
- Large Financing Scale: Cerebras raised $5.55 billion in its IPO at a price of $185 per share, opening at $350, which, despite subsequent declines, demonstrates strong market demand and investor interest.
- Optimistic Analyst Ratings: Morgan Stanley rated Cerebras as 'Overweight' with a price target of $250, highlighting its unique advantages in AI infrastructure, especially as demand for fast inference grows, positioning the company for significant benefits.
- Significant Collaboration Potential: Needham analysts noted Cerebras' $20 billion compute deal with OpenAI and collaboration with AWS, underscoring its unique position in fast inference workloads and the potential for substantial revenue growth in the future.
See More
US Stocks Show Mixed Performance as Tech Stocks Rebound
- Market Performance: The S&P 500 rose by 0.3% and the Nasdaq 100 jumped 1.6%, while the Dow Jones fell by 0.2%, indicating a positive impact from the rebound in tech stocks despite ongoing geopolitical risks in the Middle East.
- Chip Industry Update: Intel secured an order for over 3 million specialized AI chips from Google, significantly boosting its stock price on Monday, highlighting the continued investment and demand for AI technology from major tech players, which may enhance Intel's market share.
- Airline Cost Pressures: Rising jet fuel prices driven by geopolitical tensions pushed U.S. passenger airlines' fuel expenses up 78% year-over-year in April to nearly $6.5 billion, indicating significant cost challenges that could impact future profitability in the industry.
- Investor Sentiment: Despite Apple's introduction of Siri AI at WWDC 2026, the lack of a clear launch timeline led to a nearly 2% drop in its stock price, reflecting cautious market sentiment towards new technology releases while indicating ongoing investor focus on tech stocks.
See More
Trump Bull Market May End, Pharma Stocks to Continue Winning
- Market Performance Review: Since President Trump's inauguration, the S&P 500 has surged over 23%, reflecting strong investor demand for high-growth companies, particularly in innovative sectors like AI and quantum computing.
- Eli Lilly's Growth Potential: Eli Lilly (LLY) leads the obesity drug market with products like Mounjaro and Zepbound, which continue to see revenue growth in double and triple digits, and the newly launched oral weight loss drug Foundayo is expected to broaden its market reach.
- Strong Financial Performance: Johnson & Johnson (JNJ) reported sales growth in its innovative medicines and medtech sectors, with an 11% increase in innovative medicine sales and a 7.7% rise in medtech, totaling nearly $24 billion in sales, demonstrating resilience amid economic fluctuations.
- Future Growth Targets: Johnson & Johnson aims to achieve $100 billion in annual revenue this year and double-digit growth by the end of the decade, supported by its portfolio of 28 products generating over $1 billion annually, which is expected to drive stock price increases.
See More
S&P 500 Rises 23% Since Trump's Inauguration Amid Growth Stocks Surge
- Market Growth Trend: Since President Trump's inauguration, the S&P 500 has surged over 23%, reflecting strong investor interest in high-growth sectors, particularly in innovative areas like artificial intelligence and quantum computing, which have driven overall market gains.
- Pharmaceutical Market Leader: Eli Lilly is leading the obesity drug market, with its products Mounjaro and Zepbound experiencing revenue growth in double and triple digits, and the recent launch of the oral weight loss drug Foundayo is expected to broaden its market reach.
- Strong Financial Performance: Johnson & Johnson reported nearly 10% sales growth in its innovative medicines and medtech sectors, with total sales exceeding $24 billion in the latest quarter, indicating robust growth potential in the healthcare market.
- Future Growth Expectations: Johnson & Johnson aims to achieve $100 billion in annual revenue by 2023 and anticipates double-digit growth by the end of the decade, suggesting that demand for its medical products will remain strong even amid economic fluctuations, positioning the stock for continued appreciation.
See More
Mixed US Stock Market on Monday, AI Enthusiasm Boosts Chip Stocks
- Chipmaker Recovery: Following last Friday's selloff, chipmakers and AI-infrastructure stocks saw a modest recovery on Monday, with Intel (INTC) rising over 11% after Google placed an order for three million Tensor Processing Units, indicating sustained market demand for AI technology.
- Oil Price Volatility: WTI crude oil prices initially surged over 4% on Monday due to Iran's announcement of an end to military operations against Israel, but later retreated, highlighting market sensitivity to geopolitical risks and affecting investor demand for safe-haven assets.
- Interest Rate Expectations Shift: The market is pricing in only a 3% chance of a 25 bp rate hike at the upcoming FOMC meeting in June, reflecting investor concerns over slowing economic growth, which pushed the 10-year T-note yield to a two-week high of 4.580%, indicating tension over future monetary policy.
- Mixed International Market Performance: Overseas stock markets settled mixed on Monday, with the Euro Stoxx 50 falling to a two-week low while China's Shanghai Composite dropped 1.70%, demonstrating the impact of global economic uncertainty on market sentiment.
See More
SpaceX IPO Set to Become Largest in History
- Lowered IPO Threshold: Fidelity has reduced the minimum account balance for the SpaceX IPO to $2,000, significantly below the traditional six-figure requirement, potentially allowing more retail investors to participate and increasing their share allocation.
- Opportunities for Retail Investors: SpaceX plans to allocate up to 30% of shares to retail investors, far exceeding the typical 5% to 10%, which may provide ordinary investors with better access to purchase at the $135 offering price.
- Market Risk Warning: While the lowered threshold appears to offer opportunities for retail investors, it raises questions about SpaceX's motivations, particularly regarding whether it is creating smoother exit liquidity for early investors ahead of the IPO.
- Cautious Investment Advice: Investors should remain vigilant; although the lowered threshold may seem inclusive, it could also serve as a strategy for institutions planning to sell shares, prompting retail investors to carefully assess their investment size based on personal risk profiles.
See More
Cerebras Shares Rebound as Wall Street Initiates Coverage
- Positive Market Reaction: Cerebras shares rose 5% in premarket trading on Monday, reflecting investor confidence in the newly public chipmaker, particularly after Wall Street initiated coverage, indicating recognition of its unique capabilities.
- Large Financing Scale: Cerebras raised $5.55 billion in its IPO at a price of $185 per share, opening at $350, which, despite subsequent declines, demonstrates strong market demand and investor interest.
- Optimistic Analyst Ratings: Morgan Stanley rated Cerebras as 'Overweight' with a price target of $250, highlighting its unique advantages in AI infrastructure, especially as demand for fast inference grows, positioning the company for significant benefits.
- Significant Collaboration Potential: Needham analysts noted Cerebras' $20 billion compute deal with OpenAI and collaboration with AWS, underscoring its unique position in fast inference workloads and the potential for substantial revenue growth in the future.
See More
US Stocks Show Mixed Performance as Tech Stocks Rebound
- Market Performance: The S&P 500 rose by 0.3% and the Nasdaq 100 jumped 1.6%, while the Dow Jones fell by 0.2%, indicating a positive impact from the rebound in tech stocks despite ongoing geopolitical risks in the Middle East.
- Chip Industry Update: Intel secured an order for over 3 million specialized AI chips from Google, significantly boosting its stock price on Monday, highlighting the continued investment and demand for AI technology from major tech players, which may enhance Intel's market share.
- Airline Cost Pressures: Rising jet fuel prices driven by geopolitical tensions pushed U.S. passenger airlines' fuel expenses up 78% year-over-year in April to nearly $6.5 billion, indicating significant cost challenges that could impact future profitability in the industry.
- Investor Sentiment: Despite Apple's introduction of Siri AI at WWDC 2026, the lack of a clear launch timeline led to a nearly 2% drop in its stock price, reflecting cautious market sentiment towards new technology releases while indicating ongoing investor focus on tech stocks.
See More
Trump Bull Market May End, Pharma Stocks to Continue Winning
- Market Performance Review: Since President Trump's inauguration, the S&P 500 has surged over 23%, reflecting strong investor demand for high-growth companies, particularly in innovative sectors like AI and quantum computing.
- Eli Lilly's Growth Potential: Eli Lilly (LLY) leads the obesity drug market with products like Mounjaro and Zepbound, which continue to see revenue growth in double and triple digits, and the newly launched oral weight loss drug Foundayo is expected to broaden its market reach.
- Strong Financial Performance: Johnson & Johnson (JNJ) reported sales growth in its innovative medicines and medtech sectors, with an 11% increase in innovative medicine sales and a 7.7% rise in medtech, totaling nearly $24 billion in sales, demonstrating resilience amid economic fluctuations.
- Future Growth Targets: Johnson & Johnson aims to achieve $100 billion in annual revenue this year and double-digit growth by the end of the decade, supported by its portfolio of 28 products generating over $1 billion annually, which is expected to drive stock price increases.
See More
S&P 500 Rises 23% Since Trump's Inauguration Amid Growth Stocks Surge
- Market Growth Trend: Since President Trump's inauguration, the S&P 500 has surged over 23%, reflecting strong investor interest in high-growth sectors, particularly in innovative areas like artificial intelligence and quantum computing, which have driven overall market gains.
- Pharmaceutical Market Leader: Eli Lilly is leading the obesity drug market, with its products Mounjaro and Zepbound experiencing revenue growth in double and triple digits, and the recent launch of the oral weight loss drug Foundayo is expected to broaden its market reach.
- Strong Financial Performance: Johnson & Johnson reported nearly 10% sales growth in its innovative medicines and medtech sectors, with total sales exceeding $24 billion in the latest quarter, indicating robust growth potential in the healthcare market.
- Future Growth Expectations: Johnson & Johnson aims to achieve $100 billion in annual revenue by 2023 and anticipates double-digit growth by the end of the decade, suggesting that demand for its medical products will remain strong even amid economic fluctuations, positioning the stock for continued appreciation.
See More
Mixed US Stock Market on Monday, AI Enthusiasm Boosts Chip Stocks
- Chipmaker Recovery: Following last Friday's selloff, chipmakers and AI-infrastructure stocks saw a modest recovery on Monday, with Intel (INTC) rising over 11% after Google placed an order for three million Tensor Processing Units, indicating sustained market demand for AI technology.
- Oil Price Volatility: WTI crude oil prices initially surged over 4% on Monday due to Iran's announcement of an end to military operations against Israel, but later retreated, highlighting market sensitivity to geopolitical risks and affecting investor demand for safe-haven assets.
- Interest Rate Expectations Shift: The market is pricing in only a 3% chance of a 25 bp rate hike at the upcoming FOMC meeting in June, reflecting investor concerns over slowing economic growth, which pushed the 10-year T-note yield to a two-week high of 4.580%, indicating tension over future monetary policy.
- Mixed International Market Performance: Overseas stock markets settled mixed on Monday, with the Euro Stoxx 50 falling to a two-week low while China's Shanghai Composite dropped 1.70%, demonstrating the impact of global economic uncertainty on market sentiment.
See More
SpaceX IPO Set to Become Largest in History
- Lowered IPO Threshold: Fidelity has reduced the minimum account balance for the SpaceX IPO to $2,000, significantly below the traditional six-figure requirement, potentially allowing more retail investors to participate and increasing their share allocation.
- Opportunities for Retail Investors: SpaceX plans to allocate up to 30% of shares to retail investors, far exceeding the typical 5% to 10%, which may provide ordinary investors with better access to purchase at the $135 offering price.
- Market Risk Warning: While the lowered threshold appears to offer opportunities for retail investors, it raises questions about SpaceX's motivations, particularly regarding whether it is creating smoother exit liquidity for early investors ahead of the IPO.
- Cautious Investment Advice: Investors should remain vigilant; although the lowered threshold may seem inclusive, it could also serve as a strategy for institutions planning to sell shares, prompting retail investors to carefully assess their investment size based on personal risk profiles.
See More
